Reducing treatment-related morbidity and mortality in early-stage Hodgkin's disease and why the recent southwest oncology group trial is not the way to go

Journal of Clinical Oncology

Volumn 20, Issue 9, 2002, Pages 2225-2228

  Prosnitz, Leonard R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENICITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG INDUCED DISEASE; EDITORIAL; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LAPAROTOMY; MORBIDITY; MORTALITY; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SECOND CANCER; TREATMENT OUTCOME;

EID: 0036569739     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.9.2225     Document Type: Editorial

References (42)

1. The role of radiotherapy for early stage Hodgkin's disease: Limitations and perspectives
2. Radiation therapy in clinical stage I and II Hodgkin's disease: The Princess Margaret Hospital Lymphoma Group
3. Radiation therapy in the management of Hodgkin's disease
4. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation
5. The role of radiation in the management of Hodgkin's disease: An update
6. The value of laparotomy and splenectomy in the staging of Hodgkin's disease
7. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease
8. Prognostic factors for positive surgical staging in patients with Hodgkin's disease
9. Role of laparotomy and splenectomy in the management of Hodgkin's disease
10. Influence of clinical trials on current treatment strategy for Hodgkin's disease
11. Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group
12. The management of Hodgkin's disease: Half a century of change - The Kaplan Memorial Lecture
13. Long-term complications of laparotomy in Hodgkin's disease
14. Effect of postoperative radiotherapy on the development of small bowel obstruction in patients undergoing staging laparotomy for Hodgkin's disease
15. Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: Emphasis on the role of exploratory laparotomy and fractionation
16. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease
17. Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin's disease
18. Coronary artery disease mortality in patients treated for Hodgkin's disease
19. Incidence of second cancers in patients treated for Hodgkin's disease
20. Late toxicity of radiotherapy in Hodgkin's disease: The role of fraction size
21. Cardiac disease following treatment of Hodgkin's disease in children and adolescents
22. Long-term complications of treatment and causes of mortality after Hodgkin's disease
23. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: An international collaborative study among cancer registries
24. Long-term survival in Hodgkin's disease
25. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence
26. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
27. Solid second cancers following Hodgkin's disease
28. Breast cancer after treatment of Hodgkin's disease
29. Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas
30. Second neoplasms in patients with Hodgkin's disease following combined modality therapy: The Yale experience
31. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease
32. The EORTC trials for limited stage Hodgkin's disease: The EORTC Lymphoma Cooperative Group
33. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data
34. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma
35. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study
36. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90
37. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease
38. Comparison of highdose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease: An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania
39. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease
40. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency
41. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy